Abstract
Uncontrolled hypertension is directly associated with an increased risk of cardiovascular (CV) events and CV disease. Hypertension has been a major health care concern for decades, and numerous clinical guidelines recommend specific target blood pressure (BP) goals and evidence-based treatments. New data from outcomes studies continue to evolve after the publication of hypertension treatment guidelines. Considering the current environment of rising health care costs, managed care must continue to make decisions about how to best allocate resources for the management of hypertension. This paper reviews current clinical practice guidelines in hypertension and highlights the role that the angiotensin type II receptor blocker olmesartan medoxomil can play in the achievement and maintenance of recommended BP goals.
Keywords: Blood pressure, clinical guidelines, goal BP, hypertension, managed care, olmesartan medoxomil, angiotensinogen, Olmesartan medoxomil.
5